China National Accord Medicines Corp Ltd
SZSE:000028
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/E
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Valuation Scenarios
If P/E returns to its 3-Year Average (12.8), the stock would be worth ¥26.06 (5% upside from current price).
| Scenario | P/E Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 12.2 | ¥24.8 |
0%
|
| 3-Year Average | 12.8 | ¥26.06 |
+5%
|
| 5-Year Average | 12 | ¥24.56 |
-1%
|
| Industry Average | 33.5 | ¥68.41 |
+176%
|
| Country Average | 29.6 | ¥60.47 |
+144%
|
Forward P/E
Today’s price vs future net income
| Today's Market Cap | Net Income | Forward P/E | ||
|---|---|---|---|---|
|
¥14.8B
|
/ |
Jan 2026
¥1.1B
|
= |
|
|
¥14.8B
|
/ |
Dec 2026
¥1.2B
|
= |
|
|
¥14.8B
|
/ |
Dec 2027
¥1.1B
|
= |
|
|
¥14.8B
|
/ |
Dec 2028
¥1.2B
|
= |
|
Forward P/E shows whether today’s P/E still looks high or low once future net income are taken into account.
Peer Comparison
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| CN |
C
|
China National Accord Medicines Corp Ltd
SZSE:000028
|
13.8B CNY | 12.2 | |
| US |
|
Mckesson Corp
NYSE:MCK
|
100.3B USD | 23.1 | |
| US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
60.7B USD | 37.4 | |
| US |
|
Cencora Inc
NYSE:COR
|
59.9B USD | 36.9 | |
| US |
|
Cardinal Health Inc
NYSE:CAH
|
45.5B USD | 27.4 | |
| AU |
|
Sigma Healthcare Ltd
ASX:SIG
|
32B AUD | 35.3 | |
| CN |
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
62.8B CNY | 11 | |
| CN |
|
Huadong Medicine Co Ltd
SZSE:000963
|
58.8B CNY | 20.7 | |
| US |
|
Henry Schein Inc
NASDAQ:HSIC
|
8.6B USD | 21.7 | |
| KR |
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW | 89.6 | |
| CN |
|
Sinopharm Group Co Ltd
HKEX:1099
|
58.6B HKD | 7.2 |
Market Distribution
| Min | 0 |
| 30th Percentile | 17.1 |
| Median | 29.6 |
| 70th Percentile | 57.7 |
| Max | 43 569.3 |
Other Multiples
China National Accord Medicines Corp Ltd
Glance View
China National Accord Medicines Corp Ltd, nestled within the bustling healthcare landscape of China, operates at the heart of the pharmaceutical distribution and retail sectors. Established with the goal of ensuring that essential medicines and healthcare services are accessible to the vast Chinese population, the company has built an extensive distribution network. This network efficiently links manufacturers with hospitals, clinics, and pharmacies, making certain that a myriad of pharmaceutical products reach their intended destinations. By leveraging a combination of logistical prowess and vast geographical coverage, the company adeptly navigates the complexities of supply chain management, underscoring its role as a critical player in China's healthcare infrastructure. Beyond distribution, China National Accord Medicines also capitalizes on the booming retail pharmaceuticals market through its chain of pharmacies. These retail outlets serve as direct points of sale to consumers, offering both prescription and over-the-counter medications, alongside health consultation services. This dual focus on both wholesale distribution and retail outlets enables the company to capture value across the supply chain, from manufacturer to end-user. The strategic alignment of its operations streamlines efficiency and generates revenue, sustaining its growth amid a fiercely competitive and rapidly evolving market. Through this integrated approach, the company solidifies its position as a crucial conduit in the delivery of healthcare solutions across China.